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Abstract 
Background:  Brugada syndrome is an arrhythmogenic disease characterized by an ECG 
pattern of ST-segment elevation in the right precordial leads and an increase risk of sudden 
cardiac  death.  Risk  stratification  for  the  life-threatening  arrhythmic  events   in  Brugada 
syndrome is not yet established. In the present study, we report our experience in patients with 
Brugada syndrome, following an ICD implantation.                                                   
Methods and Results: A total of 12 patients (11 men, 1 woman) with a mean age of 46.5±11.8 
were studied. At diagnosis, 7 patients had syncope of unknown origin, 2 patients were 
asymptomatic, 2 patients were survivors of cardiac arrest, and 1 had documented clinical VT 
requiring direct cardioversion for termination. Age was similar between the symptomatic and 
asymptomatic patients (46.6±13 vs. 46±2.8, respectively). Two patients reported a family 
history of sudden cardiac death. In 3 patients, spontaneous coved-type ECG was found at 
baseline. In 9 patients, a class I antiarrhythmic drug administration unmasked the characteristic 
type I ECG. In 4 patients (2 symptomatic with syncope at presentation and 2 asymptomatic), 
who underwent PES, sustained polymorphic VT or VF was induced. VF was induced by single 
extrastimuli in 2 symptomatic patients (1 from RV apex and 1 from RVOT). In 2 asymptomatic 
patients, VF was induced by two and triple ventricular extrastimli (1 from RV apex and 1 from 
RVOT). None of them experienced an event during follow-up. No significant difference was 
found between symptomatic and asymptomatic patients (p=NS). The mean follow-up period 
for the entire study population was 27.83±11.25 months. During follow-up, 2 patients (one 
with prior cardiac arrest and another with syncope) had VF. Both of them had a type I ECG 
after provocation with a class I antiarrhythmic drug. None of them had undergone programmed 
ventricular stimulation. Five patients (41.7 %) had inappropriate ICD interventions during 
follow-up. The cause of inappropriate therapy was sinus tachycardia in 2 patients, AF in 2 
patients and T wave oversensing in 1 patient.                                                               
Conclusions: Knowledge about Brugada syndrome is steadily progressing but there are still 
unanswered issues dealing with the risk stratification and the management of patients.
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Introduction
            Brugada syndrome is an arrhythmogenic disease characterized by an ECG pattern of 
ST-segment elevation in the right precordial leads and increased risk of sudden cardiac death 
(SCD)   as   a   result   of   polymorphic   ventricular   tachycardia   or   ventricular   fibrillation.1
               Studies on the prognosis of patients with asymptomatic Brugada syndrome have 
reported different incidences of ventricular arrhythmias and SCD, ranging from 0.0% to 
8.0%.2-4  Nevertheless, asymptomatic Brugada syndrome has been elucidated as having a lower 
risk compared with symptomatic Brugada syndrome.                                                       
            Although great progress has been made in the identification and characterization of 
patients with Brugada syndrome, the implantable cardioverter defibrillator (ICD) remains the 
only proven treatment to prevent sudden death. ICD therapy, however, is not trivial for this 
frequently young patient population in whom multiple ICD replacements are expected. In 
addition,  for   many   patients,   ICD   implantation   is   not   an   option  because   of   economic 
constraints.5,6
            In the present study, we report our experience in patients with Brugada syndrome for 
whom ICD  was  implanted.                                                                                 
Materials   and   Methods                                                                                
            The study population consisted of 12 patients (11 males, 1 woman) with Brugada 
syndrome, who underwent ICD implantation in our center. Brugada syndrome was diagnosed 
after an episode of aborted cardiac arrest, during diagnostic evaluation of syncope of unknown 
origin or during study of family members of patients with the syndrome, when the following 
criteria were met: 1) Type 1 ECG pattern as defined by coved-type ST-segment elevation ≥ 2 
mm or 0.2mV followed by a negative T wave in the right precordial leads at baseline or after 
administration of a class I antiarrhythmic drug. 2) the absence of apparent heart disease based 
on   the   results   of   echocardiography,  cardiac   catheterization,   and  coronary   angiography.
Electrophysiological   study                                                                    
               An Electrophysiologic study (PES) was performed in 4 patients, 2 patients with 
symptomatic Brugada syndrome and 2 with asymptomatic Brugada syndrome. PES was not 
performed in 5 symptomatic patients with syncope because they were diagnosed before the 
report of the second consensus conference by Heart rhythm society and the European heart 
rhythm association. Programmed ventricular stimulation (PVS) was performed at 2-ms and 
twice the diastolic threshold current from the right ventricular apex (RVA) and the RVOT, 
using three basic cycle lengths (600-500 and 400) and a maximum of triple extrastimuli. The 
endpoints of PVS were either induction of VF or a sustained ventricular tachyarrhythmia 
(lasting >30 seconds, causing syncope or requiring intervention to be terminated) or completion 
of   PES   protocol.   No   patients   received   antiarrhythmic   drugs   before   PES.
            All patients were followed up at the outpatient clinic. During follow-up, patients were 
considered to have an arrhythmic event if sudden death occurred or VF was documented in the 
storage memory of the ICD.                                                                                 
Statistical   Analysis                                                                          
            Continuous variables are expressed as mean ± SD and range and discrete variables are 
expressed as percentage. Fisher exact test and chi-square test were used to compare categorical 
variables between groups. A level of p < 0.05 was considered as statistically significant.
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Study   limitation                                                                                    
            The principle limitation in this study is the small number of patients. The second 
limitation is mean follow-up of 27.83±11.25 months, which is too short to allow for definitive 
conclusion about the prognosis of patients with Brugada syndrome.                            
Results
            Table 1 shows the baseline characteristics of patients, Electrophysiologic study data 
and events during follow-up. The population consisted of 12 patients (11 men, 1 woman) with 
a mean age of 46.5±11.8 (median 44years; 20-68 years). At diagnosis, 7 patients had syncope 
of unknown origin, 2 patients were asymptomatic, 2 patients were survivors of cardiac arrest, 
and 1 had documented clinical VT requiring direct cardioversion for termination. Of 2 
asymptomatic   patients,   one   was   identified   during   a   routine   ECG   which   revealed   the 
characteristic coved-type ECG pattern of Brugada syndrome and another during family 
screening. Age was similar between the symptomatic and asymptomatic patients (46.6±13 vs. 
46±2.8, respectively). Two patients noted a family history of sudden cardiac death, one of them 
presented with syncope and another had clinical VT associated with hemodynamic collapse. 
None of them experienced an event during follow-up.
Table 1. Baseline characteristics of patients 
ECG Parameters and Electrophysiological Study                                                                       
            In 3 patients, spontaneous coved-type ECG (type I ECG) was found that was defined at 
baseline (Figure 1). In 9 patients, a class I antiarrhythmic drug administration unmasked the 
characteristic type I ECG. In 4 patients (2 symptomatic with syncope at presentation and 2 
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asymptomatic), who underwent PES, sustained polymorphic VT or VF was induced. VF was 
induced by single extrastimuli in 2 symptomatic patients (1 from RV apex and 1 from RVOT). 
In 2 asymptomatic patients, VF was induced by two and triple ventricular extrastimli (1 from 
RV apex and 1 from RVOT). No significant difference was found between symptomatic and 
asymptomatic patients (p=NS).
Figure 1: Twelve lead surface ECG showing typical coved-type ST-elevation in right 
precordial leads
Therapy   and   Follow-up                                                                  
            The mean follow-up period for the entire study population was 27.83±11.25 months. 
During follow-up, 2 patients (one with prior cardiac arrest and another with syncope) had a 
new arrhythmic event (ICD intervention as a result of VF). Both of them had a type I ECG 
after provocation with a class I antiarrhythmic drug. None of them had undergone programmed 
ventricular stimulation. The period from diagnosis to arrhythmic event ranged from 1 to 2 
months.  
            Five patients (41.7 %) had inappropriate ICD interventions during follow-up. The cause 
of inappropriate therapy was sinus tachycardia in 2 patients, AF in 2 patients and T wave 
oversensing in 1 patient. In all patients except one who experienced an inappropriate ICD 
intervention, class I antiarrhythmic drug administration unmasked the diagnostic type I ECG. 
Three of them had undergone PES and were inducible (1 with single, 1 with double and 1 with 
triple   extrastimuli,   respectively).                                                                        
            Two patients had a family history of sudden cardiac death, but 3 patients had other 
family members with Brugada syndrome.  The patient number 2 presented with frequent ICD 
(Marquis VR 7230, Medtronic Inc., Minneapolis, MN, USA) discharges, two years after 
implantation. Device interrogation revealed intermittent T wave oversensing due to changes in 
R:T ratio  which could not be resolved by device reprogramming and required implantation of 
a new sense /pace lead   in another position where an R wave of greater amplitude made 
oversensing less likely (Figure 2). In patient number 7, quinidine eliminated repetitive VF 
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episodes, known as electrical storm. Therefore, quinidine was continued in combination with 
ICD. Neither syncope nor ventricular tachycardia occurred during the administration of 
quinidine. 
Figure 2: Electrocardiographic recording of oversensing of T wave 
resulted in the misdiagnosis of sinus tachycardia as ventricular fibrillation
Discussion
            Brugada syndrome is an inherited disease that challenges our knowledge. Despite the 
major advances accomplished during the last decade, there are still unanswered issues dealing 
with the management of Brugada syndrome. The role of PES for risk stratification is debated. 
Some investigators supported the view that both symptomatic patients and asymptomatic 
patients who are inducible by PES are best managed by the implantation of an ICD.7,8 
However, more recent data, supported the view that given the low predictive accuracy of PES, 
cardiac arrest survivors and patients with a history of syncope or a family history of juvenile 
SCD should receive an ICD.4,9                                                                               
            There is consensus that the severity of the clinical manifestation is the most powerful 
indicator of outcome and those survivors of cardiac arrest and patients with a spontaneous 
diagnostic pattern with a history of syncope are at higher risk of cardiac events and should 
receive an ICD without undergoing PES.10  In our series, 2 patients who experienced an 
appropriate shock of ICD had a history of syncope and aborted sudden cardiac death. 
Inappropriate ICD interventions were found in 41.7% of our series during follow-up. Eckardt et 
al,11 in their study questioned the widespread use of defibrillators in patients with a Brugada 
ECG but no previous cardiac arrest or syncope. It remains unclear what risk of sudden death is 
acceptable in a young person. Hence, aggressive management of these individuals may be 
difficult on the basis of the lethality of the events but has to be weighed against the economic 
costs and the costs in terms of quality of life, including the risk for inappropriate shocks. In our 
patients, 2 asymptomatic patients and 2 symptomatic patients who received an ICD based on 
PES   inducibility   did   not   experience   an   appropriate   shock   during   follow-up.  
            We showed the high inducibility of VF by less extrastimuli in our symptomatic patients 
that was concordant with the degree of inducibility reported in previous studies.2,4,9,12       
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            Marked beneficial effect of quinidine was observed in one of our patients, whose 
repetitive VF episodes were eliminated. Taking into account the beneficial electrophysiological 
and clinical effects of quinidine observed in a small number of patients with the Brugada 
syndrome12,13, and the antiarrhythmic effectiveness in experimental models14 , further studies 
of oral quinidine or other Ito  blockers in patients with the Brugada syndrome should be 
encouraged.
            The limited follow-up period in our series may explain the lack of events during follow-
up. In the presence of low statistical power because of the limited number of events; we could 
not find the predictors of adverse outcome.                                                           
Conclusion
               Knowledge about Brugada syndrome is steadily progressing but there are still 
controversies about the risk stratification, especially concerning the value of PES. Management 
of asymptomatic patients is still debated and no conclusive evidence exists to guide risk 
stratification in this subgroup. A central issue in this study is  inappropriate ICD interventions 
in 41% of the patients that raise questions about its routine implantation in patients.  The major 
unresolved question is to determine the criteria for the advisability of ICD implantation.  
            Appropriate clinical trials are needed to establish the role of antiarrhythmic therapy in 
selected patient populations with the Brugada syndrome.
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